1
|
Kikuchi Y, Oyama K, Yoshida T, Naruse D, Tsutsui M, Kunioka S, Wakabayashi N, Kamiya H. Insulin therapy maintains the performance of PVA-coated PCL grafts in a diabetic rat model. Biomater Sci 2022; 10:5208-5215. [PMID: 35894180 DOI: 10.1039/d2bm00531j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Vascular tissue engineering has shown promising results in "healthy" animal models. However, studies on the efficacy of artificial grafts under "pathological conditions" are limited. Therefore, in this study, we aimed to characterize the performance of polyvinyl alcohol (PVA)-coated poly-ε-caprolactone (PCL) grafts (PVA-PCL grafts) under diabetic conditions. To this end, PCL grafts were produced via electrospinning and coated with the hydrophilic PVA polymer, while a diabetic rat model (DM) was established via streptozotocin injection. Thereafter, the performance of the graft in the infrarenal abdominal aorta of the rats was evaluated in vivo. Thus, we observed that the healthy group showed CD31 positive/αSM positive cells in the graft lumen. Further, the patency rate of the PVA-PCL graft was 100% at 2 weeks (n = 7), while all the DM rats (n = 8) showed occluded grafts. However, the treatment of DM rats with neutral protamine Hagedorn insulin (tDM) significantly improved the patency rate (100%; n = 5). Furthermore, the intimal coverage rate corresponding to the tDM group was comparable to that of the healthy group at 2 weeks (tDM vs. healthy: 16.1% vs. 14.7%, p = 0.931). Therefore, the present study demonstrated that the performance of the PVA-PCL grafts was impaired in DM rats; however, insulin treatment reversed this impairment. These findings highlighted the importance of using a model that more closely resembles the cases that are encountered in clinical practice to achieve a clinically applicable vascular graft with a small diameter.
Collapse
Affiliation(s)
- Yuta Kikuchi
- Department of Cardiac Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
| | - Kyohei Oyama
- Department of Cardiac Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
| | - Takumi Yoshida
- Life Materials Development Section, Human Life Technology Research Institute, Toyama Industrial Technology Research and Development Center, Toyama, Japan
| | - Daisuke Naruse
- Business Development section, Business Development and Quality Control Department, Iaazaj Holdings Co., Ltd, Toyama, Japan
| | - Masahiro Tsutsui
- Department of Cardiac Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
| | - Shingo Kunioka
- Department of Cardiac Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
| | - Naohiro Wakabayashi
- Department of Cardiac Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
| | - Hiroyuki Kamiya
- Department of Cardiac Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
| |
Collapse
|